Postmenopausal estrogen–progestin therapy and breast cancer: a clinical response to epidemiological reports

References

• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000; 283: 485–91
   PubMed Web of Science ®Google Scholar
• Schairer C, Byrne C, Keyl P M, Brinton L A, Sturgeon S R, Hooever R N. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491–500
   PubMed Web of Science ®Google Scholar
• Willett W C, Colditz G, Stampfer M. Postmenopausal estrogens - opposed, unopposed, or none of the above. J Am Med Assoc 2000; 283: 534–5
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59
   PubMed Web of Science ®Google Scholar
• Nurses' Health Study Research Group, Colditz G, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 1998; 147((Suppl)), abstr 254
   Google Scholar
• Ross R K, Paganini-Hill A, Wan P C, Pike M C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32
   PubMed Web of Science ®Google Scholar
• Colditz G A, Hankinson S E, Hunter D J, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron J A, Correia N, Bergström R, Adami H O, Persson I. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339–44
   PubMed Web of Science ®Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253–60
   PubMed Web of Science ®Google Scholar
• Kaufman D W, Miller D R, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. J Am Med Assoc 1984; 252: 63–7
   PubMed Web of Science ®Google Scholar
• Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–8
   PubMed Web of Science ®Google Scholar
• Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293
   PubMed Web of Science ®Google Scholar
• Yang C P, Daling J R, Band P R, Gallagher R P, White E, Weiss N S. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992; 3: 475
   PubMed Web of Science ®Google Scholar
• Stanford J L, Weiss N S, Voigt L F, Daling J R, Habel L A, Rossing M A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995; 274: 137
   PubMed Web of Science ®Google Scholar
• Newcomb P A, Longnecker M P, Storer B E, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995; 142: 788–95
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Negri E, Franceschi S. Hormone replacement therapy and breast cancer risk: a cooperative Italian study. Br J Cancer 1995; 72: 244–8
   PubMed Web of Science ®Google Scholar
• Brinton L A, Brogan D R, Coates R J, Swanson C A, Potischman N, Stanford J L. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998; 5: 145–51
   PubMed Web of Science ®Google Scholar
• Gambrelli RD, Jr, Maier R C, Sanders B I. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983; 62: 435
   PubMed Web of Science ®Google Scholar
• Nachtigall M J, Smilen S W, Nachtigall R AD, Nachtigall R H, Nachtigall L I. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80: 827–30
   PubMed Web of Science ®Google Scholar
• Bergkvist L, Adami H-O, Persson I, Bergström R, Krusemo U B. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221–7
   PubMed Web of Science ®Google Scholar
• Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080
   PubMedGoogle Scholar
• Henderson B E, Paganini-Hill A, Ross R K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–8
   PubMed Web of Science ®Google Scholar
• Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–32
   PubMed Web of Science ®Google Scholar
• Willis D B, Calle E E, Miracle-McMahill H L, Heath CW, Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449–57
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Colditz G A, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75
   PubMed Web of Science ®Google Scholar
• Sellers T A, Mink P J, Cerhan J R, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127: 973–80
   PubMed Web of Science ®Google Scholar
• Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91: 264–70
   PubMed Web of Science ®Google Scholar
• Fowble B, Hanlon A, Greedman G, et al. Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 1999; 17: 1680–8
   PubMed Web of Science ®Google Scholar
• Jernström H, Frenander J, Fernö M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999; 80: 1453–8
   PubMed Web of Science ®Google Scholar
• Strickland D M, Gambrell RD, Jr, Butzin C A, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400
   PubMed Web of Science ®Google Scholar
• Bonnier P, Romain S, Giacalone P L, Laffargue F, Martin P M, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11
   PubMed Web of Science ®Google Scholar
• Bonnier P, Bessenay F, Sasco A J, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998; 79: 278–82
   PubMed Web of Science ®Google Scholar
• Salmon R J, Ansquer Y, Asselain B, Languille O, Lesec G, Remvikos Y. Clinical and biological characteristics of breast cancers in postmenopausal women receiving hormone replacement therapy for menopause. Oncol Rep 1999; 6: 699–703
   PubMed Web of Science ®Google Scholar
• LaCroix A Z, Burke W. Breast cancer and hormone replacement therapy. Lancet 1997; 350: 1042–3
   PubMed Web of Science ®Google Scholar
• Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996; 38: 325–34
   PubMed Web of Science ®Google Scholar
• Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998; 16: 3115–20
   PubMed Web of Science ®Google Scholar
• O'Connor I F, Shembekar M V, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immuno-histological study. J Clin Pathol 1998; 51: 935–8
   PubMed Web of Science ®Google Scholar
• Bilimoria M M, Winchester D J, Sener S F, Motykie G, Sehgal U L, Winchester D P. Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 1999; 6: 200–7
   PubMed Web of Science ®Google Scholar
• Cobleigh M A, Norlock F E, Oleske D M, Starr A. Hormone replacement therapy and high S phase in breast cancer. J Am Med Assoc 1999; 281: 1528–30
   Web of Science ®Google Scholar
• Squitieri R, Tartter P, Ahmed S, Brower S T. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994; 178: 167–70
   PubMed Web of Science ®Google Scholar
• Harding C, Knox W F, Faragher E B, Baildam A, Bundred N J. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Br Med J 1996; 312: 1646–7
   PubMed Web of Science ®Google Scholar
• Stolier A J, Mera R, Schapira D. The impact of current use of hormone replacement therapy on prognostic factors and surgical treatment of new breast cancers. Oncol Rep 1998; 5: 61–4
   PubMed Web of Science ®Google Scholar
• LeBlanc E S, Viscoli C M, Heinrich J B. Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. J Women's Health Gender-Based Med 1999; 8: 815–23
   PubMedGoogle Scholar
• Ferguson D P, Anderson T J. Morphological evaluation of cell turnover in relation to menstrual cycle in the ‘resting’ human breast. Br J Cancer 1988; 44: 177
   Google Scholar
• Longacre T A, Bartow S A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382
   PubMed Web of Science ®Google Scholar
• Going J J, Anderson T J, Battersby S, MacIntyre C C. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193
   PubMed Web of Science ®Google Scholar
• Söderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 1993; 168: 874–9
   PubMed Web of Science ®Google Scholar
• Potten C S, Watson R J, Williams G T, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163–70
   PubMed Web of Science ®Google Scholar
• Vogel P M, Georgiade N G, Fetter B F, Vogel F S, McCarty K S. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981; 104: 23–4
   PubMed Web of Science ®Google Scholar
• Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997; 176: 123–8
   PubMed Web of Science ®Google Scholar
• Spicer D V, Krecker E A, Pike M. The endocrine prevention of breast cancer. Cancer Invest 1995; 13: 495–504
   PubMed Web of Science ®Google Scholar
• Clarke C L, Sutherland R L. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11: 266
   PubMed Web of Science ®Google Scholar
• Graham J D, Clarke C L. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18: 502–19
   PubMed Web of Science ®Google Scholar
• Key T JA, Pike M C. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29–43
   PubMedGoogle Scholar
• Henderson B E, Ross R K, Judd H L, Krailo M D, Pike M C. Do regular ovulatory cycles increase breast cancer risk?. Cancer 1985; 56: 1206
   PubMed Web of Science ®Google Scholar
• Anderson T J, Ferguson D JP, Raab G M. Cell turnover in the ‘resting’ human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982; 46: 376–82
   PubMed Web of Science ®Google Scholar
• McMichael-Phillips D F, Harding C, Morton M, Roberts S A, Howell A. The effects of soy supplementation on epithelial proliferation in the normal human breast. Breast Cancer Res Treat 1996; 41: 263
   Google Scholar
• Shyamala G. Roles of estrogen and progesterone in normal mammary gland development. Insights from progesterone receptor null mutant mice and in situ localization of receptor. Trends Endocrinol Metab 1997; 8: 34–9
   PubMed Web of Science ®Google Scholar
• Chang K-J, Lee T TY, Linarez-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle. in vivo. Fertil Steril 1995; 63: 785–91
   PubMed Web of Science ®Google Scholar
• Laidlaw I J, Clarke R B, Howell A, Owen A W, Potten C S, Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1996; 136: 164–71
   Web of Science ®Google Scholar
• Helzlsouer K J, Alberg A J, Bush T L, Longcope C, Gordon G B, Comstock G W. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994; 18: 79
   PubMedGoogle Scholar
• Gompel A, Malet C, Spritzer P, Lalardrie J-P, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986; 63: 1174
   PubMed Web of Science ®Google Scholar
• Foidart J-M, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69: 963–9
   PubMed Web of Science ®Google Scholar
• Cline J M, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93–100
   PubMed Web of Science ®Google Scholar
• Kester H A, Van der Leede B M, Van der Saag P T, Van der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 1997; 272: 16637–43
   PubMed Web of Science ®Google Scholar
• Hargreaves D F, Knox F, Swindell R, Potten C S, Bundred N J. Epithelial proliferation and hormone receptor status in the normal postmenopausal breast and the effects of hormone replacement therapy. Br J Cancer 1998; 78: 945–9
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Le M G, Sitruk-Ware R, Thalabard J C, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994; 70: 270–7
   PubMed Web of Science ®Google Scholar
• Musgrove E A, Hamilton J A, Lee C S, Sweeney K J, Watts C K, Sutherland R L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577–87
   PubMed Web of Science ®Google Scholar
• Hurd C, Khattree N, Alban P, et al. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 1995; 270: 28507–10
   PubMed Web of Science ®Google Scholar
• Clarke R B, Howell A, Potten C S, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987–91
   PubMed Web of Science ®Google Scholar
• Yeel D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 1994; 32: 85–95
   PubMed Web of Science ®Google Scholar
• Musgrove E A, Lee C S, Sutherland R L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991; 11: 5032–43
   PubMed Web of Science ®Google Scholar